{"id":1891,"date":"2025-03-28T07:02:45","date_gmt":"2025-03-28T07:02:45","guid":{"rendered":"https:\/\/journal.nncf.kz\/?p=1891"},"modified":"2025-04-23T09:39:39","modified_gmt":"2025-04-23T09:39:39","slug":"features-of-lung-damage-in-anca-associated-vasculitis","status":"publish","type":"post","link":"https:\/\/journal.nncf.kz\/en\/features-of-lung-damage-in-anca-associated-vasculitis\/","title":{"rendered":"FEATURES OF LUNG DAMAGE IN ANCA-ASSOCIATED VASCULITIS"},"content":{"rendered":"

\u041f\u043e\u0441\u0442\u0443\u043f\u0438\u043b\u0430 \u0432 \u0440\u0435\u0434\u0430\u043a\u0446\u0438\u044e: 19 \u044f\u043d\u0432\u0430\u0440\u044f 2025 \u0433.
\n\u041f\u0440\u0438\u043d\u044f\u0442\u0430 \u043a \u043f\u0443\u0431\u043b\u0438\u043a\u0430\u0446\u0438\u0438: 4 \u043c\u0430\u0440\u0442\u0430 2025 \u0433.
\n\u041e\u043f\u0443\u0431\u043b\u0438\u043a\u043e\u0432\u0430\u043d\u0430 online: 28 \u043c\u0430\u0440\u0442\u0430 2025 \u0433.
\n\u0423\u0414\u041a 616.24-001\/.131.14-002
\nDOI: 10.26212\/2227-1937.2025.47.32.015<\/a>
\nM. T. Abdullayeva1,2
\n1 Research Institute of Cardiology and Internal Diseases of the Ministry of Health of the Republic of Kazakhstan,
\nAlmaty, the Republic of Kazakhstan
\n2 Asfendiyarov Kazakh National Medical University,
\nAlmaty, the Republic of Kazakhstan
\nFEATURES OF LUNG DAMAGE IN ANCA-ASSOCIATED VASCULITIS
\nIntroduction. Systemic vasculitis is a large area of disease characterized by the induction of inflammation in the vessel wall
\ndue to various immune disorders. The formation of anti-neutrophil cytoplasmic antibodies which determine the development
\nof the so-called anti-neutrophil cytoplasmic antibodies-associated vasculitis is of the variants of such disorders: microscopic
\npolyangiitis, granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis) and eosinophilic
\ngranulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome). These features determine the exceptional
\nimportance of understanding their pathologic behaviour, clinical picture, and treatment, which will be discussed in this
\narticle
\nObjectives: The main goal of the article is to investigate the frequency of lung damage in patients with ANCA-SV, to assess
\ntheir impact on the course, and to adequately select immunosuppressive therapy that allows for achieving disease remission.
\nTo identify the incidence of lung damage in patients with ANCA-SV.
\nTo track the dynamics of pulmonary function indicators and outcomes of ANCA-SV under the treatment.
\nMaterial and methods: To do this, we conducted a retrospective analysis of the medical records of 50 patients with a clinical
\ndiagnosis of ANCA-SV who were treated in the Department of Internal Medicine No. 2 of the Research Institute of Cardiology
\nand Internal Diseases in Almaty, the Republic of Kazakhstan, through 2015 to 2024. The diagnosis was verified based on a life
\nhistory, physical examination, immunological study (detection of ANCA), as well as by assessing kidney function indicators
\n(creatinine, urea, electrolytes, the presence of proteins, diuresis volume), assessing pulmonary function indicators
\n(spirography, peakflowmetry), instrumental survey such as CT scan of the chest, MRI of the brain, sinuses.
\nResults and discussion.
\n29 women and 21 men aged 25 to 75 (average 50 years) were identified among those suffering from ANCA-SV. Our goal was
\nto investigate the incidence of lung damage in patients with ANCA-SV. To do this, we have conducted some survey methods.
\nIn most cases, changes in the lungs were confirmed by clinical data, decreased saturation, laboratory parameters (general
\nsputum analysis, sputum culture for MTB and GeneXpert), and results of an immunological blood test: enzyme multiplied
\nimmunoassay (Immunoglobulin E), CT scan of the chest, \u0441hest X-ray, spirography, blood gases test.
\nAmong 50 patients with ANCA-SV, changes in the lungs were detected in 28 patients. Changes in the lungs with ANCA-SV are
\ndifferent. Some patients experience more than two changes in the lungs.
\nConclusions: Lung damage in the form of infiltrates, cavities of destruction, diffuse alveolar damage, interstitial fibrosis,
\npleurisy and bronchial asthma, destructive processes, ventilation disorders, changes in the lungs in the form of granulomas,
\npulmonary hemorrhages are symptoms of ANCA-SV. Timely hospitalization and modern diagnostic methods make it possible
\nnot only to determine the causes of pulmonary complications in the shortest possible time but also to begin therapy as
\nquickly as possible and obtain a positive clinical response to treatment. ANCA-associated vasculitis is a difficult condition to
\ndiagnose, which is characterized by a high rate of progression, and malignancy and leads to the death of the patient in a short
\ntime. However, advances in medicine and pharmacology with the discovery of genetically engineered biological therapy
\n(Rituximab) have improved the prognosis for patients.
\nKeywords: systemic vasculitis: lung damage, microscopic polyangiitis, Wegener’s disease, Churg-Strauss syndrome<\/p>\n

\r\n\t\"\"\r\n\r\n\t
\r\n\t\t\u0421\u043a\u0430\u0447\u0430\u0442\u044c: FEATURES OF LUNG DAMAGE IN ANCA-ASSOCIATED VASCULITIS<\/a>\r\n\t\t
<\/div>\r\n\t\t
\u0421\u043a\u0430\u0447\u0430\u043d\u043e: 118, \u0440\u0430\u0437\u043c\u0435\u0440: 880.5 KB<\/div>\r\n\t<\/div>\r\n\t\r\n<\/div>\r\n\r\n